Compare GSK plc (GSK) vs Invesco S&P 500 Low Volatility ETF (SPLV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Invesco S&P 500 Low Volatility ETF — how do they compare? GSK plc trades at $46.82 (market cap $91.88B), while Invesco S&P 500 Low Volatility ETF trades at $71.97 (market cap $6.94B). The key difference: GSK plc is far larger — about 13.2× Invesco S&P 500 Low Volatility ETF's market cap, and GSK plc pays a 3.9% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Invesco S&P 500 Low Volatility ETF for 123 Days on average.
| GSK | SPLV | |
|---|---|---|
Market Cap | $91.88B | $6.94B |
Volume | 7,730,529 | 1,663,703 |
Sector | Health | — |
52-Week High | $61.18 | $77.97 |
52-Week Low | $43.24 | $70.30 |
Typical Hold Time | 93 Days | 123 Days |
Enterprise Value | $111.88B | — |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% with a P/E of 14.89, trading below industry averages. The stock shows strong profitability with 72.73% gross margins and 29.73% ROE, though technical indicators signal bearish momentum. Recent earnings beats and strategic oncology investments highlight growth potential amid patent cliff concerns.
GSK's valuation appears attractive with earnings momentum, but faces headwinds from technical weakness and HIV patent expirations. The bullish analyst sentiment (31% buy ratings) and pipeline innovation provide upside, while cost-saving initiatives and dividend yield offer stability. Key risks include competitive pressures and execution on £40B sales targets.
SPLV trades at $71.22, down 0.71% with a bearish technical outlook. The ETF shows neutral oscillators but bearish moving averages, with key resistance at $72. Recent news highlights sector overweights in Utilities and Real Estate as headwinds, with the fund lagging the S&P 500's performance. Dividend payments of $0.14 are scheduled for July and September 2026.
Outlook remains cautious due to technical weakness and unappealing growth-adjusted valuation. Risks include concentrated sector exposure and macroeconomic pressures. The fund's low-volatility strategy may appeal during market uncertainty, but current technicals suggest limited near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →
